An inhibitor of PAD4 deimination activity (IC50 = 5.9 μM) that also inhibits PAD1 and PAD3 (IC50 = 0.8 and 6.2 μM, respectively); dose dependently decreases the citrulline content in serum and joints and reduces the development of IgG autoantibodies in a CIA mouse model of inflammatory arthritis.